101709-4 |
Avoiding external reminders of the stressful experience (for example, people, places, conversations, activities, objects, or situations) |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Avoiding external reminders of the stressful experience (for example, people, places, conversations, activities, objects, or situations) [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101709-4 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Avoiding external reminders of the stressful experience (for example, people, places, conversations, activities, objects, or situations)? |
N |
|
1 month; 1 month (30 days); 30 days; EXT; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
10171-7 |
Symptoms & diseases |
Hx |
Eyes |
Pt |
Nar |
|
|
ACTIVE |
History of Eyes disorders Narrative |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10171-7 |
|
|
|
|
|
|
|
|
0 |
Hx of Eyes disorders |
|
|
|
|
|
H+P; H+P.HX; History; Narrative; Ophthalmologic; P prime; Point in time; Random; Report; Sx; Symp + dis; Vision; Visual |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component, changed Property from "Find" to "Hx", and removed "Reported" Method per 8/2015 Clinical LOINC Committee decision |
0 |
101710-2 |
Trouble remembering important parts of the stressful experience |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Trouble remembering important parts of the stressful experience [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101710-2 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Trouble remembering important parts of the stressful experience? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101711-0 |
Loss of interest in activities that you used to enjoy |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Loss of interest in activities that you used to enjoy [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101711-0 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Loss of interest in activities that you used to enjoy? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101712-8 |
Feeling distant or cut off from other people |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Feeling distant or cut off from other people [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101712-8 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Feeling distant or cut off from other people? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Othr; QL; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101713-6 |
Trouble experiencing positive feelings (for example, being unable to feel happiness or have loving feelings for people close to you) |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Trouble experiencing positive feelings (for example, being unable to feel happiness or have loving feelings for people close to you) [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101713-6 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Trouble experiencing positive feelings (for example, being unable to feel happiness or have loving feelings for people close to you)? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Pos; QL; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101714-4 |
Irritable behavior, angry outbursts, or acting aggressively |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Irritable behavior, angry outbursts, or acting aggressively [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101714-4 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Irritable behavior, angry outbursts, or acting aggressively? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101715-1 |
Being superalert or watchful or on guard |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Being superalert or watchful or on guard [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101715-1 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Being superalert or watchful or on guard? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101716-9 |
Feeling jumpy or easily startled |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Feeling jumpy or easily startled [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101716-9 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Feeling jumpy or easily startled? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101717-7 |
Having difficulty concentrating |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Having difficulty concentrating [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101717-7 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Having difficulty concentrating? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101718-5 |
Trouble falling or staying asleep |
Find |
^Patient |
1Mo |
Ord |
PCL-5 |
|
ACTIVE |
Trouble falling or staying asleep [PCL-5] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
101718-5 |
|
PCL-5 |
|
|
Observation |
|
|
|
0 |
|
|
|
Trouble falling or staying asleep? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101719-3 |
Nickel Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Nickel IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
[IU]/mL |
|
|
|
|
|
|
ALLERGY |
|
101719-3 |
|
|
|
|
Both |
|
|
|
0 |
Nickel IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Immune globulin E; Immunoglobulin E; NI; Ni IgE; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
10172-5 |
Symptoms & diseases |
Hx |
Hematologic system |
Pt |
Nar |
|
|
ACTIVE |
History of Hematologic system disorders Narrative |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10172-5 |
|
|
|
|
|
|
|
|
0 |
Hx of Hematologic disorders |
|
|
|
|
|
H+P; H+P.HX; Hemato; History; Narrative; P prime; Point in time; Random; Report; Sx; Symp + dis |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component, changed Property from "Find" to "Hx", and removed "Reported" Method per 8/2015 Clinical LOINC Committee decision |
0 |
101720-1 |
Disability status |
Imp |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Disability status |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HL7.CCDA |
|
101720-1 |
|
|
|
|
Observation |
|
|
|
0 |
Disability status |
|
|
|
N |
|
HL7CCDA; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101721-9 |
SARS coronavirus 2 RNA |
- |
Respiratory |
Pt |
- |
Probe.amp.tar |
|
DEPRECATED |
Deprecated SARS-CoV-2 (COVID-19) in Respiratory specimen by NAA with probe detection |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101721-9 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
Deprecated SARS-CoV-2 Resp NAA+probe |
|
|
|
N |
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; II; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Ribonucleic acid; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SDA; Severe Acute Respiratory Syndrome; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral Pneumonias; Wuhan coronavirus |
2.76 |
2.75 |
|
Panel |
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
101724-3 |
Certolizumab Ab |
MCnc |
Ser/Plas |
Pt |
Qn |
SPR |
|
ACTIVE |
Certolizumab Ab [Mass/volume] in Serum or Plasma by SPR |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101724-3 |
|
SPR |
|
|
Observation |
|
|
|
0 |
Certolizumab Ab SerPl SPR-mCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cimzia�®; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Surface plasmon resonance spectroscopy |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
101727-6 |
JC virus DNA |
LaCnc |
Urine |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
JC virus DNA [log units/volume] (viral load) in Urine by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
Log IU/mL |
|
|
|
|
|
|
MICRO |
|
101727-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
JCPyV DNA Ur NAA+probe-Log IU |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Human polyomavirus 2; JC Polyomavirus; JCPyV; JCV; John Cunningham Virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Log ACNC; Log IU; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; UA; UR; Urn; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
{Log_IU}/mL |
|
|
|
0 |
101729-2 |
JC virus DNA |
ACnc |
Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
JC virus DNA [Units/volume] (viral load) in Plasma by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
101729-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
JCPyV DNA Plas NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Human polyomavirus 2; JC Polyomavirus; JCPyV; JCV; John Cunningham Virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
10173-3 |
Symptoms & diseases |
Hx |
Musculoskeletal system |
Pt |
Nar |
|
|
ACTIVE |
History of Musculoskeletal system disorders Narrative |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10173-3 |
|
|
|
|
|
|
|
|
0 |
Hx of Musculoskeletal disorders |
|
|
|
|
|
H+P; H+P.HX; History; Narrative; P prime; Point in time; Random; Report; Sx; Symp + dis |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component, changed Property from "Find" to "Hx", and removed "Reported" Method per 8/2015 Clinical LOINC Committee decision |
0 |
101731-8 |
JC virus DNA |
LaCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
JC virus DNA [log units/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
Log IU/mL |
|
|
|
|
|
|
MICRO |
|
101731-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
JCPyV DNA SerPl NAA+probe-Log IU |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Human polyomavirus 2; JC Polyomavirus; JCPyV; JCV; John Cunningham Virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Log ACNC; Log IU; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
{Log_IU}/mL |
|
|
|
0 |
101732-6 |
JC virus DNA |
LaCnc |
CSF |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
JC virus DNA [log units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
Log IU/mL |
|
|
|
|
|
|
MICRO |
|
101732-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
JCPyV DNA CSF NAA+probe-Log IU |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Human polyomavirus 2; JC Polyomavirus; JCPyV; JCV; John Cunningham Virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Log ACNC; Log IU; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
{Log_IU}/mL |
|
|
|
0 |
101733-4 |
JC virus DNA |
ACnc |
Urine |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
JC virus DNA [Units/volume] (viral load) in Urine by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
101733-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
JCPyV DNA Ur NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Human polyomavirus 2; JC Polyomavirus; JCPyV; JCV; John Cunningham Virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; UA; UR; Urn; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
101734-2 |
Sodium Urate crystals |
EngDiff |
Urine |
24H |
Qn |
|
|
ACTIVE |
Sodium Urate crystals [Energy Difference] in 24 hour Urine |
|
NAM |
DefinitionDescription |
|
|
Delta G (kJ/mol) |
|
|
|
|
|
|
CHEM |
|
101734-2 |
|
|
|
|
Both |
|
|
|
0 |
Na Urate cry 24h EngDiff Ur |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Crys; Cryst; Crystal; Monosodium Urate; Na; Na Urate; Na Urate cry; Na+; NaU; QNT; Quan; Quant; Quantitative; UA; UR; Urates; Uric acid; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
kJ/mol |
|
|
|
0 |
101735-9 |
Urate crystals |
EngDiff |
Urine |
24H |
Qn |
|
|
ACTIVE |
Urate crystals [Energy Difference] in 24 hour Urine |
|
NAM |
DefinitionDescription |
|
|
kJ/mol |
|
|
|
|
|
|
CHEM |
|
101735-9 |
|
|
|
|
Both |
|
|
|
0 |
Urate Cry 24h EngDiff Ur |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Crys; Cryst; Crystal; QNT; Quan; Quant; Quantitative; UA; UR; Urates; Uric acid; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
kJ/mol |
|
|
|
0 |
101736-7 |
Brushite crystals |
EngDiff |
Urine |
24H |
Qn |
|
|
ACTIVE |
Calcium hydrogen phosphate dihydrate (CHPD) in 24 hour Urine |
|
NAM |
DefinitionDescription |
|
|
kJ/mol |
|
|
|
|
|
|
CHEM |
|
101736-7 |
|
|
|
|
Both |
|
|
|
0 |
Ca H2 Phos dihyd (CHPD) 24h Ur |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Crys; Cryst; Crystal; QNT; Quan; Quant; Quantitative; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
kJ/mol |
|
|
|
0 |